Interferon-mediated anti-angiogenic therapy for neuroblastoma
- 18 October 2005
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 228 (1-2) , 163-170
- https://doi.org/10.1016/j.canlet.2004.11.063
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Immunomodulatory effects of high‐dose and low‐dose interferon α2b in patients with high‐risk resected melanomaCancer, 2002
- Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In VivoJournal of Virology, 2001
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- TNP-470 antiangiogenic therapy for advanced murine neuroblastomaJournal of Pediatric Surgery, 1997
- Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male VolunteersJournal of Interferon & Cytokine Research, 1996
- The implications of angiogenesis for the biology and therapy of cancer metastasisCell, 1994
- Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brainNature Genetics, 1994
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Microvascular Injury in Pathogenesis of Interferon-Induced Necrosis of Subcutaneous Tumors in MiceJNCI Journal of the National Cancer Institute, 1989
- Virus interference. II. Some properties of interferonProceedings of the Royal Society of London. B. Biological Sciences, 1957